|Bid||141.38 x 1200|
|Ask||142.00 x 1300|
|Day's range||140.95 - 149.75|
|52-week range||115.61 - 497.49|
|Beta (5Y monthly)||1.69|
|PE ratio (TTM)||4.18|
|Earnings date||03 Aug 2022 - 08 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||219.33|
In the latest trading session, Moderna (MRNA) closed at $145.36, marking a +0.76% move from the previous day.
Pfizer (PFE) and partner BioNTech's (BNTX) Omicron-specific COVID vaccine candidates achieves a higher immune response against the variant in a phase II/III study.
Moderna (NASDAQ: MRNA) waited a long time to reach this important moment: the authorization of its vaccine in infants and children. This month, the FDA authorized the vaccine for both teens and children ages six months and older, and vaccine rollout has begun for the youngest group. Could this new authorization be Moderna's ticket to long-term success?